Skip to main content
. Author manuscript; available in PMC: 2018 Dec 10.
Published in final edited form as: J Control Release. 2017 Sep 25;267:100–118. doi: 10.1016/j.jconrel.2017.09.026

Figure 7.

Figure 7

(A) Synthesis of CPT-PTX-Sup35 from the reaction of dCys-Sup35 with a 1:1mixture of activated disulfide drugs, CPT-buSS-Pyr and PTX-buSS-Pyr. (B) Representative TEM images of CPT-PTX-Sup35 in water. (C) Release of CPT and PTX and degradation of CPT-PTX-Sup35 (50 mM in 10mM sodium phosphate solution, pH 7.4) in the presence or absence of 10 mM GSH (○ CPT-PTX-Sup35 without GSH; ◊ CPT-PTX-Sup35 with GSH; ◇ released CPT; □ released PTX). (D). Cytotoxicity of CPT-PTX-Sup35 against PTX-resistant KB-V1 cervical cancer cells (○ CPT-PTX-Sup35; □ PTX; ◇dPTX-Sup35). Cell viability was determined by SRB assay after 48 h incubation with the appropriate drug-containing media. (Adapted from Ref. [172] with permission)